Results 261 to 270 of about 519,368 (313)

Pharmacology and Clinical Pharmacology of Vigabatrin

Journal of Child Neurology, 1991
Vigabatrin is an enzyme-activated, irreversible inhibitor of γ-aminobutyric acid (GABA) aminotransferase, which causes a marked increase in cerebral GABA concentration and a resulting anticonvulsant action. Recovery from its effects requires the synthesis of new enzyme, and this may take several days following a single dose.
openaire   +2 more sources

Clinical pharmacology in Australia

Clinical Pharmacology & Therapeutics, 1974
In Australia, clinical pharmacology is a small but developing discipline useful for the generation of data concerning the efficacy and safety of new therapeutic substances. While most clinical pharmacology is carried on as an adiunct to the interests of a specialist in some branch of internal medicine, there are now, in Australia, four units titled ...
openaire   +4 more sources

Clinical pharmacology

To design therapeutic trials and select the most appropriate substance and dose for an indication, a detailed understanding of clinical pharmacology is crucial. In recent years, several studies have explored the human pharmacology of different psychedelics and 3,4-methylendioxymethylamphetamin (MDMA).
Severin B, Vogt, Matthias E, Liechti
openaire   +2 more sources

CLINICAL PHARMACOLOGY OF BENZODIAZEPINES

Annual Review of Medicine, 1987
The benzodiazepines are the most widely used anxiolytic drugs. Their pharmacokinetic properties differ widely. Side effects are usually mild but dependence can supervene after long-term administration, even if normal therapeutic doses are not exceeded. Careful monitoring of use is essential.
openaire   +2 more sources

Clinical pharmacology of glipizide

The American Journal of Medicine, 1983
The clinical pharmacology of glipizide and other sulfonylureas is briefly reviewed. Reevaluation of the University Group Diabetes Program data suggests that sulfonylureas do not increase cardiovascular mortality. Instead, a long-term study of subjects with impaired glucose tolerance indicates that sulfonylureas reduce the frequency of cardiovascular ...
A, Melander, E, Wåhlin-Boll
openaire   +2 more sources

Pharmacology and clinical pharmacology of organic nitrates

European Journal of Clinical Pharmacology, 1990
Current concepts and future aspects of pharmacological interventions in the treatment of coronary heart disease have been compiled. Especially new insights in the pathophysiology of coronary heart disease e.g. the dynamic pathology of coronary atherosclerosis, possible role of endothelin in vasospasm, as well as new pharmacodynamic and pharmacokinetic ...
openaire   +2 more sources

Clinical pharmacology in Nigeria

Clinical Pharmacology & Therapeutics, 1974
Nigeria, today, with a strongly developing economy, is laying the fQUndation for future achievement. While there is no specific unit of clinical pharmacology yet in the country, the principle is recognized and the need appreciated. There are many features in Nigeria that, if properly appreciated and utilized, will aid the progression of clinical ...
openaire   +2 more sources

Clinical Pharmacology of Digoxin

Pediatric Clinics of North America, 1972
Although digoxin is invaluable for a variety of cardiovascular diseases, and it is virtually the only cardiac glycoside in common use today in children and infants, it is known to have a low margin of safety. A central goal of this paper is to aid the education of clinicians so as to alter a traditional mode of administering digoxin, that of pushing to
openaire   +2 more sources

Clinical Pharmacology of Lacidipine

Journal of Cardiovascular Pharmacology, 1991
The safety and tolerability of lacidipine was assessed in a volunteer population, and its pharmacodynamic and pharmacokinetic profiles evaluated. In normotensive subjects, single oral doses of 3-5 mg of lacidipine produced a dose-related fall in peripheral vascular resistance.
S T, Hall, S M, Harding, G L, Evans, M, Pellegatti, P, Rizzini   +4 more
openaire   +2 more sources

Clinical pharmacology of thalidomide

European Journal of Clinical Pharmacology, 2001
Thalidomide has a chiral centre, and the racemate of (R)- and (S)-thalidomide was introduced as a sedative drug in the late 1950s. In 1961, it was withdrawn due to teratogenicity and neuropathy. There is now a growing clinical interest in thalidomide due to its unique anti-inflammatory and immunomodulatory effects.To critically review pharmacokinetic ...
T, Eriksson, S, Björkman, P, Höglund
openaire   +2 more sources